Skip to main content

Advertisement

Figure 6 | Molecular Cancer

Figure 6

From: Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway

Figure 6

EZH2 regulated miR-200b expression and mesenchymal-epithelial transition in MPNST cells. (A) qRT-PCR analyses of miR-200b in MPNST724, S462, and STS26T cells transfected with a negative control or EZH2 siRNA. miR-200b expression was normalized to SNORD47. Data are shown as mean ± SD (n = 3); *p < 0.05, Student t test. (B) qRT-PCR analyses of miR-200b in S462 and MPNST724 cells treated with DZNep for 72 hours. miR-200b expression was normalized to SNORD47. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (C) Promoter activity assay showed that EZH2 knockdown increased miR-200b promoter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (D) Luciferase reporter assay showed that EZH2 knockdown inhibited miR-200b target reporter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05, Student t test. (E) Promoter activity assay showed that DZNep treatment induced miR-200b promoter activity in S462 cells. Mean ± SD values are shown (n = 3); *p < 0.05; Student t test. (F) Luciferase reporter assay showed that DZNep treatment suppressed miR-200b target reporter activity in S462 cells. Mean ± SD values are shown (n = 3); **p < 0.01, Student t test. (G) Western blot analyses of EZH2, vimentin, E-cadherin, and actin in MPNST724, S462, and STS26T cells transfected with a negative control or EZH2 siRNA.

Back to article page